Analysts at Wedbush assumed coverage on shares of Nightstar Therapeutics PLC (NASDAQ:NITE) in a research note issued on Monday. The firm set an “outperform” rating on the stock.

A number of other brokerages also recently commented on NITE. Jefferies Group LLC started coverage on shares of Nightstar Therapeutics PLC in a research note on Monday. They issued a “buy” rating on the stock. BMO Capital Markets started coverage on shares of Nightstar Therapeutics PLC in a research note on Monday. They set an “outperform” rating on the stock.

Nightstar Therapeutics PLC (NASDAQ NITE) opened at 19.00 on Monday. Nightstar Therapeutics PLC has a 52 week low of $14.56 and a 52 week high of $24.93. The firm’s market cap is $533.92 million. The company’s 50 day moving average is $18.97 and its 200-day moving average is $18.97.

ILLEGAL ACTIVITY NOTICE: “Nightstar Therapeutics PLC (NITE) Research Coverage Started at Wedbush” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/23/nightstar-therapeutics-plc-nite-research-coverage-started-at-wedbush.html.

About Nightstar Therapeutics PLC

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Receive News & Stock Ratings for Nightstar Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics PLC and related stocks with our FREE daily email newsletter.